AustralieFrV1, PascalFrancis, Corpus, bibRecord, 000179

Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes

Identifieur interne : 000179 ( PascalFrancis/Corpus ); précédent : 000178; suivant : 000180

Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes

Auteurs : Sophia Zoungas ; Mark Woodward ; QIANG LI ; Mark E. Cooper ; Pavel Hamet ; Stephen Harrap ; Simon Heller ; Michel Marre ; Anushka Patel ; Neil Poulter ; Bryan Williams ; John Chalmers

Source :

Diabetologia : (Berlin) [ 0012-186X ] ; 2014.

RBID : Pascal:14-0277006

Descripteurs français

Pascal (Inist)
- Age, Diagnostic, Durée, Facteur risque, Microangiopathie, Mortalité, Diabète de type 2, Artériopathie oblitérante.

English descriptors

KwdEn :
- Age, Diagnosis, Duration, Microangiopathy, Mortality, Occlusive arterial disease, Risk factor, Type 2 diabetes.

Abstract

Aims/hypothesis Data are inconsistent regarding the associations between age, age at diagnosis of diabetes, diabetes duration and subsequent vascular complications. Methods The associations between age (or age at diagnosis), diabetes duration and major macrovascular events, all-cause death and major microvascular events were examined in 11,140 patients with type 2 diabetes randomly allocated to intensive or standard glucose control in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Rates were calculated by 5 year baseline age (or age at diagnosis) and diabetes duration strata. Risks were estimated using Cox models adjusted for treatment assignment and HbA_1c. Results The mean age (±SD) was 65.8±6.4 years, age at diagnosis was 57.8±8.7 years and diabetes duration was 7.9±6.4 years. Diabetes duration was associated with the risk of macrovascular events (HR 1.13 [95% CI 1.08, 1.17]), microvascular events (1.28 [1.23, 1.33]) and death (1.15 [1.10, 1.20]) whereas age (or age at diagnosis) was only associated with the risk of macrovascular events (1.33 [1.27, 1.39]) and death (1.56 [1.48, 1.64]). No interaction was observed between diabetes duration, age and the risk of macrovascular events or death (both p>0.4). However, an interaction was observed between diabetes duration, age and the risk of microvascular events (p=0.002), such that the effects of increasing diabetes duration were greatest at younger rather than older age. Conclusions/interpretation In patients with type 2 diabetes, age or age at diagnosis and diabetes duration are independently associated with macrovascular events and death whereas only diabetes duration is independently associated with microvascular events and this effect is greater in the youngest patients.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0012-186X`
A03		`1`		`@0 Diabetologia : (Berl.)`
A05				`@2 57`
A06				`@2 12`
A08	`01`	`1`	`ENG`	`@1 Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes`
A11	`01`	`1`		`@1 ZOUNGAS (Sophia)`
A11	`02`	`1`		`@1 WOODWARD (Mark)`
A11	`03`	`1`		`@1 QIANG LI`
A11	`04`	`1`		`@1 COOPER (Mark E.)`
A11	`05`	`1`		`@1 HAMET (Pavel)`
A11	`06`	`1`		`@1 HARRAP (Stephen)`
A11	`07`	`1`		`@1 HELLER (Simon)`
A11	`08`	`1`		`@1 MARRE (Michel)`
A11	`09`	`1`		`@1 PATEL (Anushka)`
A11	`10`	`1`		`@1 POULTER (Neil)`
A11	`11`	`1`		`@1 WILLIAMS (Bryan)`
A11	`12`	`1`		`@1 CHALMERS (John)`
A14	`01`			`@1 The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road @2 Camperdown, Sydney, NSW 2050 @3 AUS @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 9 aut. @Z 12 aut.`
A14	`02`			`@1 School of Public Health and Preventive Medicine, Monash University @2 Melbourne, VIC @3 AUS @Z 1 aut.`
A14	`03`			`@1 Department of Epidemiology, Johns Hopkins University @2 Baltimore, MD @3 USA @Z 2 aut.`
A14	`04`			`@1 Baker IDI Heart and Diabetes Institute @2 Melbourne, VIC @3 AUS @Z 4 aut.`
A14	`05`			`@1 Research Centre, Centre hospitalier de l'Université de Montréal @2 Montreal, QC @3 CAN @Z 5 aut.`
A14	`06`			`@1 The Royal Melbourne Hospital, University of Melbourne @2 Melbourne, VIC @3 AUS @Z 6 aut.`
A14	`07`			`@1 University ot Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust @2 Sheffield @3 GBR @Z 7 aut.`
A14	`08`			`@1 Hôpital Bichat-Claude Bernard and Université Paris 7 @2 Paris @3 FRA @Z 8 aut.`
A14	`09`			`@1 International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College @2 London @3 GBR @Z 10 aut.`
A14	`10`			`@1 Institute of Cardiovascular Science, University College @2 London @3 GBR @Z 11 aut.`
A17	`01`	`1`		`@1 ADVANCE Collaborative group @3 INC`
A20				`@1 2465-2474`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13012 @5 354000504569210060`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 22 ref.`
A47	`01`	`1`		`@0 14-0277006`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Diabetologia : (Berlin)`
A66	`01`			`@0 DEU`
C01	`01`		`ENG`	@0 Aims/hypothesis Data are inconsistent regarding the associations between age, age at diagnosis of diabetes, diabetes duration and subsequent vascular complications. Methods The associations between age (or age at diagnosis), diabetes duration and major macrovascular events, all-cause death and major microvascular events were examined in 11,140 patients with type 2 diabetes randomly allocated to intensive or standard glucose control in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Rates were calculated by 5 year baseline age (or age at diagnosis) and diabetes duration strata. Risks were estimated using Cox models adjusted for treatment assignment and HbA_1c. Results The mean age (±SD) was 65.8±6.4 years, age at diagnosis was 57.8±8.7 years and diabetes duration was 7.9±6.4 years. Diabetes duration was associated with the risk of macrovascular events (HR 1.13 [95% CI 1.08, 1.17]), microvascular events (1.28 [1.23, 1.33]) and death (1.15 [1.10, 1.20]) whereas age (or age at diagnosis) was only associated with the risk of macrovascular events (1.33 [1.27, 1.39]) and death (1.56 [1.48, 1.64]). No interaction was observed between diabetes duration, age and the risk of macrovascular events or death (both p>0.4). However, an interaction was observed between diabetes duration, age and the risk of microvascular events (p=0.002), such that the effects of increasing diabetes duration were greatest at younger rather than older age. Conclusions/interpretation In patients with type 2 diabetes, age or age at diagnosis and diabetes duration are independently associated with macrovascular events and death whereas only diabetes duration is independently associated with microvascular events and this effect is greater in the youngest patients.
C02	`01`	`X`		`@0 002B21E01A`
C02	`02`	`X`		`@0 002B12B03`
C03	`01`	`X`	`FRE`	`@0 Age @5 01`
C03	`01`	`X`	`ENG`	`@0 Age @5 01`
C03	`01`	`X`	`SPA`	`@0 Edad @5 01`
C03	`02`	`X`	`FRE`	`@0 Diagnostic @5 02`
C03	`02`	`X`	`ENG`	`@0 Diagnosis @5 02`
C03	`02`	`X`	`SPA`	`@0 Diagnóstico @5 02`
C03	`03`	`X`	`FRE`	`@0 Durée @5 03`
C03	`03`	`X`	`ENG`	`@0 Duration @5 03`
C03	`03`	`X`	`SPA`	`@0 Duración @5 03`
C03	`04`	`X`	`FRE`	`@0 Facteur risque @5 04`
C03	`04`	`X`	`ENG`	`@0 Risk factor @5 04`
C03	`04`	`X`	`SPA`	`@0 Factor riesgo @5 04`
C03	`05`	`X`	`FRE`	`@0 Microangiopathie @5 07`
C03	`05`	`X`	`ENG`	`@0 Microangiopathy @5 07`
C03	`05`	`X`	`SPA`	`@0 Microangiopatía @5 07`
C03	`06`	`X`	`FRE`	`@0 Mortalité @5 08`
C03	`06`	`X`	`ENG`	`@0 Mortality @5 08`
C03	`06`	`X`	`SPA`	`@0 Mortalidad @5 08`
C03	`07`	`X`	`FRE`	`@0 Diabète de type 2 @2 NM @5 09`
C03	`07`	`X`	`ENG`	`@0 Type 2 diabetes @2 NM @5 09`
C03	`07`	`X`	`SPA`	`@0 Diabetes de tipo 2 @2 NM @5 09`
C03	`08`	`X`	`FRE`	`@0 Artériopathie oblitérante @5 12`
C03	`08`	`X`	`ENG`	`@0 Occlusive arterial disease @5 12`
C03	`08`	`X`	`SPA`	`@0 Arteriopatía oclusiva @5 12`
C07	`01`	`X`	`FRE`	`@0 Endocrinopathie @5 20`
C07	`01`	`X`	`ENG`	`@0 Endocrinopathy @5 20`
C07	`01`	`X`	`SPA`	`@0 Endocrinopatía @5 20`
C07	`02`	`X`	`FRE`	`@0 Maladie métabolique @5 21`
C07	`02`	`X`	`ENG`	`@0 Metabolic diseases @5 21`
C07	`02`	`X`	`SPA`	`@0 Metabolismo patología @5 21`
C07	`03`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 22`
C07	`03`	`X`	`ENG`	`@0 Cardiovascular disease @5 22`
C07	`03`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 22`
C07	`04`	`X`	`FRE`	`@0 Pathologie des artères @5 23`
C07	`04`	`X`	`ENG`	`@0 Arterial disease @5 23`
C07	`04`	`X`	`SPA`	`@0 Arteria patología @5 23`
C07	`05`	`X`	`FRE`	`@0 Pathologie des vaisseaux sanguins @5 24`
C07	`05`	`X`	`ENG`	`@0 Vascular disease @5 24`
C07	`05`	`X`	`SPA`	`@0 Vaso sanguíneo patología @5 24`
N21				`@1 349`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0277006 INIST
ET :	Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes
AU :	ZOUNGAS (Sophia); WOODWARD (Mark); QIANG LI; COOPER (Mark E.); HAMET (Pavel); HARRAP (Stephen); HELLER (Simon); MARRE (Michel); PATEL (Anushka); POULTER (Neil); WILLIAMS (Bryan); CHALMERS (John)
AF :	The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road/Camperdown, Sydney, NSW 2050/Australie (1 aut., 2 aut., 3 aut., 9 aut., 12 aut.); School of Public Health and Preventive Medicine, Monash University/Melbourne, VIC/Australie (1 aut.); Department of Epidemiology, Johns Hopkins University/Baltimore, MD/Etats-Unis (2 aut.); Baker IDI Heart and Diabetes Institute/Melbourne, VIC/Australie (4 aut.); Research Centre, Centre hospitalier de l'Université de Montréal/Montreal, QC/Canada (5 aut.); The Royal Melbourne Hospital, University of Melbourne/Melbourne, VIC/Australie (6 aut.); University ot Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust/Sheffield/Royaume-Uni (7 aut.); Hôpital Bichat-Claude Bernard and Université Paris 7/Paris/France (8 aut.); International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College/London/Royaume-Uni (10 aut.); Institute of Cardiovascular Science, University College/London/Royaume-Uni (11 aut.)
DT :	Publication en série; Niveau analytique
SO :	Diabetologia : (Berlin); ISSN 0012-186X; Allemagne; Da. 2014; Vol. 57; No. 12; Pp. 2465-2474; Bibl. 22 ref.
LA :	Anglais
EA :	Aims/hypothesis Data are inconsistent regarding the associations between age, age at diagnosis of diabetes, diabetes duration and subsequent vascular complications. Methods The associations between age (or age at diagnosis), diabetes duration and major macrovascular events, all-cause death and major microvascular events were examined in 11,140 patients with type 2 diabetes randomly allocated to intensive or standard glucose control in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Rates were calculated by 5 year baseline age (or age at diagnosis) and diabetes duration strata. Risks were estimated using Cox models adjusted for treatment assignment and HbA_1c. Results The mean age (±SD) was 65.8±6.4 years, age at diagnosis was 57.8±8.7 years and diabetes duration was 7.9±6.4 years. Diabetes duration was associated with the risk of macrovascular events (HR 1.13 [95% CI 1.08, 1.17]), microvascular events (1.28 [1.23, 1.33]) and death (1.15 [1.10, 1.20]) whereas age (or age at diagnosis) was only associated with the risk of macrovascular events (1.33 [1.27, 1.39]) and death (1.56 [1.48, 1.64]). No interaction was observed between diabetes duration, age and the risk of macrovascular events or death (both p>0.4). However, an interaction was observed between diabetes duration, age and the risk of microvascular events (p=0.002), such that the effects of increasing diabetes duration were greatest at younger rather than older age. Conclusions/interpretation In patients with type 2 diabetes, age or age at diagnosis and diabetes duration are independently associated with macrovascular events and death whereas only diabetes duration is independently associated with microvascular events and this effect is greater in the youngest patients.
CC :	002B21E01A; 002B12B03
FD :	Age; Diagnostic; Durée; Facteur risque; Microangiopathie; Mortalité; Diabète de type 2; Artériopathie oblitérante
FG :	Endocrinopathie; Maladie métabolique; Pathologie de l'appareil circulatoire; Pathologie des artères; Pathologie des vaisseaux sanguins
ED :	Age; Diagnosis; Duration; Risk factor; Microangiopathy; Mortality; Type 2 diabetes; Occlusive arterial disease
EG :	Endocrinopathy; Metabolic diseases; Cardiovascular disease; Arterial disease; Vascular disease
SD :	Edad; Diagnóstico; Duración; Factor riesgo; Microangiopatía; Mortalidad; Diabetes de tipo 2; Arteriopatía oclusiva
LO :	INIST-13012.354000504569210060
ID :	14-0277006

Links to Exploration step

Pascal:14-0277006

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes</title>
<author><name sortKey="Zoungas, Sophia" sort="Zoungas, Sophia" uniqKey="Zoungas S" first="Sophia" last="Zoungas">Sophia Zoungas</name>
<affiliation><inist:fA14 i1="01"><s1>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road</s1>
<s2>Camperdown, Sydney, NSW 2050</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Public Health and Preventive Medicine, Monash University</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name>
<affiliation><inist:fA14 i1="01"><s1>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road</s1>
<s2>Camperdown, Sydney, NSW 2050</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Epidemiology, Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qiang Li" sort="Qiang Li" uniqKey="Qiang Li" last="Qiang Li">QIANG LI</name>
<affiliation><inist:fA14 i1="01"><s1>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road</s1>
<s2>Camperdown, Sydney, NSW 2050</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cooper, Mark E" sort="Cooper, Mark E" uniqKey="Cooper M" first="Mark E." last="Cooper">Mark E. Cooper</name>
<affiliation><inist:fA14 i1="04"><s1>Baker IDI Heart and Diabetes Institute</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hamet, Pavel" sort="Hamet, Pavel" uniqKey="Hamet P" first="Pavel" last="Hamet">Pavel Hamet</name>
<affiliation><inist:fA14 i1="05"><s1>Research Centre, Centre hospitalier de l'Université de Montréal</s1>
<s2>Montreal, QC</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harrap, Stephen" sort="Harrap, Stephen" uniqKey="Harrap S" first="Stephen" last="Harrap">Stephen Harrap</name>
<affiliation><inist:fA14 i1="06"><s1>The Royal Melbourne Hospital, University of Melbourne</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Heller, Simon" sort="Heller, Simon" uniqKey="Heller S" first="Simon" last="Heller">Simon Heller</name>
<affiliation><inist:fA14 i1="07"><s1>University ot Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name>
<affiliation><inist:fA14 i1="08"><s1>Hôpital Bichat-Claude Bernard and Université Paris 7</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Patel, Anushka" sort="Patel, Anushka" uniqKey="Patel A" first="Anushka" last="Patel">Anushka Patel</name>
<affiliation><inist:fA14 i1="01"><s1>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road</s1>
<s2>Camperdown, Sydney, NSW 2050</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poulter, Neil" sort="Poulter, Neil" uniqKey="Poulter N" first="Neil" last="Poulter">Neil Poulter</name>
<affiliation><inist:fA14 i1="09"><s1>International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Williams, Bryan" sort="Williams, Bryan" uniqKey="Williams B" first="Bryan" last="Williams">Bryan Williams</name>
<affiliation><inist:fA14 i1="10"><s1>Institute of Cardiovascular Science, University College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name>
<affiliation><inist:fA14 i1="01"><s1>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road</s1>
<s2>Camperdown, Sydney, NSW 2050</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0277006</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0277006 INIST</idno>
<idno type="RBID">Pascal:14-0277006</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000179</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes</title>
<author><name sortKey="Zoungas, Sophia" sort="Zoungas, Sophia" uniqKey="Zoungas S" first="Sophia" last="Zoungas">Sophia Zoungas</name>
<affiliation><inist:fA14 i1="01"><s1>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road</s1>
<s2>Camperdown, Sydney, NSW 2050</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Public Health and Preventive Medicine, Monash University</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name>
<affiliation><inist:fA14 i1="01"><s1>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road</s1>
<s2>Camperdown, Sydney, NSW 2050</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Epidemiology, Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qiang Li" sort="Qiang Li" uniqKey="Qiang Li" last="Qiang Li">QIANG LI</name>
<affiliation><inist:fA14 i1="01"><s1>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road</s1>
<s2>Camperdown, Sydney, NSW 2050</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cooper, Mark E" sort="Cooper, Mark E" uniqKey="Cooper M" first="Mark E." last="Cooper">Mark E. Cooper</name>
<affiliation><inist:fA14 i1="04"><s1>Baker IDI Heart and Diabetes Institute</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hamet, Pavel" sort="Hamet, Pavel" uniqKey="Hamet P" first="Pavel" last="Hamet">Pavel Hamet</name>
<affiliation><inist:fA14 i1="05"><s1>Research Centre, Centre hospitalier de l'Université de Montréal</s1>
<s2>Montreal, QC</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harrap, Stephen" sort="Harrap, Stephen" uniqKey="Harrap S" first="Stephen" last="Harrap">Stephen Harrap</name>
<affiliation><inist:fA14 i1="06"><s1>The Royal Melbourne Hospital, University of Melbourne</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Heller, Simon" sort="Heller, Simon" uniqKey="Heller S" first="Simon" last="Heller">Simon Heller</name>
<affiliation><inist:fA14 i1="07"><s1>University ot Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name>
<affiliation><inist:fA14 i1="08"><s1>Hôpital Bichat-Claude Bernard and Université Paris 7</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Patel, Anushka" sort="Patel, Anushka" uniqKey="Patel A" first="Anushka" last="Patel">Anushka Patel</name>
<affiliation><inist:fA14 i1="01"><s1>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road</s1>
<s2>Camperdown, Sydney, NSW 2050</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poulter, Neil" sort="Poulter, Neil" uniqKey="Poulter N" first="Neil" last="Poulter">Neil Poulter</name>
<affiliation><inist:fA14 i1="09"><s1>International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Williams, Bryan" sort="Williams, Bryan" uniqKey="Williams B" first="Bryan" last="Williams">Bryan Williams</name>
<affiliation><inist:fA14 i1="10"><s1>Institute of Cardiovascular Science, University College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name>
<affiliation><inist:fA14 i1="01"><s1>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road</s1>
<s2>Camperdown, Sydney, NSW 2050</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Diabetologia : (Berlin)</title>
<title level="j" type="abbreviated">Diabetologia : (Berl.)</title>
<idno type="ISSN">0012-186X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Diabetologia : (Berlin)</title>
<title level="j" type="abbreviated">Diabetologia : (Berl.)</title>
<idno type="ISSN">0012-186X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age</term>
<term>Diagnosis</term>
<term>Duration</term>
<term>Microangiopathy</term>
<term>Mortality</term>
<term>Occlusive arterial disease</term>
<term>Risk factor</term>
<term>Type 2 diabetes</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Age</term>
<term>Diagnostic</term>
<term>Durée</term>
<term>Facteur risque</term>
<term>Microangiopathie</term>
<term>Mortalité</term>
<term>Diabète de type 2</term>
<term>Artériopathie oblitérante</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Aims/hypothesis Data are inconsistent regarding the associations between age, age at diagnosis of diabetes, diabetes duration and subsequent vascular complications. Methods The associations between age (or age at diagnosis), diabetes duration and major macrovascular events, all-cause death and major microvascular events were examined in 11,140 patients with type 2 diabetes randomly allocated to intensive or standard glucose control in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Rates were calculated by 5 year baseline age (or age at diagnosis) and diabetes duration strata. Risks were estimated using Cox models adjusted for treatment assignment and HbA<sub>1c</sub>
. Results The mean age (±SD) was 65.8±6.4 years, age at diagnosis was 57.8±8.7 years and diabetes duration was 7.9±6.4 years. Diabetes duration was associated with the risk of macrovascular events (HR 1.13 [95% CI 1.08, 1.17]), microvascular events (1.28 [1.23, 1.33]) and death (1.15 [1.10, 1.20]) whereas age (or age at diagnosis) was only associated with the risk of macrovascular events (1.33 [1.27, 1.39]) and death (1.56 [1.48, 1.64]). No interaction was observed between diabetes duration, age and the risk of macrovascular events or death (both p>0.4). However, an interaction was observed between diabetes duration, age and the risk of microvascular events (p=0.002), such that the effects of increasing diabetes duration were greatest at younger rather than older age. Conclusions/interpretation In patients with type 2 diabetes, age or age at diagnosis and diabetes duration are independently associated with macrovascular events and death whereas only diabetes duration is independently associated with microvascular events and this effect is greater in the youngest patients.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0012-186X</s0>
</fA01>
<fA03 i2="1"><s0>Diabetologia : (Berl.)</s0>
</fA03>
<fA05><s2>57</s2>
</fA05>
<fA06><s2>12</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ZOUNGAS (Sophia)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WOODWARD (Mark)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>QIANG LI</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>COOPER (Mark E.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HAMET (Pavel)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HARRAP (Stephen)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HELLER (Simon)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MARRE (Michel)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>PATEL (Anushka)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>POULTER (Neil)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>WILLIAMS (Bryan)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>CHALMERS (John)</s1>
</fA11>
<fA14 i1="01"><s1>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road</s1>
<s2>Camperdown, Sydney, NSW 2050</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>School of Public Health and Preventive Medicine, Monash University</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Epidemiology, Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Baker IDI Heart and Diabetes Institute</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Research Centre, Centre hospitalier de l'Université de Montréal</s1>
<s2>Montreal, QC</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>The Royal Melbourne Hospital, University of Melbourne</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>University ot Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Hôpital Bichat-Claude Bernard and Université Paris 7</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Institute of Cardiovascular Science, University College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>ADVANCE Collaborative group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>2465-2474</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13012</s2>
<s5>354000504569210060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>22 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0277006</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Diabetologia : (Berlin)</s0>
</fA64>
<fA66 i1="01"><s0>DEU</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Aims/hypothesis Data are inconsistent regarding the associations between age, age at diagnosis of diabetes, diabetes duration and subsequent vascular complications. Methods The associations between age (or age at diagnosis), diabetes duration and major macrovascular events, all-cause death and major microvascular events were examined in 11,140 patients with type 2 diabetes randomly allocated to intensive or standard glucose control in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Rates were calculated by 5 year baseline age (or age at diagnosis) and diabetes duration strata. Risks were estimated using Cox models adjusted for treatment assignment and HbA<sub>1c</sub>
. Results The mean age (±SD) was 65.8±6.4 years, age at diagnosis was 57.8±8.7 years and diabetes duration was 7.9±6.4 years. Diabetes duration was associated with the risk of macrovascular events (HR 1.13 [95% CI 1.08, 1.17]), microvascular events (1.28 [1.23, 1.33]) and death (1.15 [1.10, 1.20]) whereas age (or age at diagnosis) was only associated with the risk of macrovascular events (1.33 [1.27, 1.39]) and death (1.56 [1.48, 1.64]). No interaction was observed between diabetes duration, age and the risk of macrovascular events or death (both p>0.4). However, an interaction was observed between diabetes duration, age and the risk of microvascular events (p=0.002), such that the effects of increasing diabetes duration were greatest at younger rather than older age. Conclusions/interpretation In patients with type 2 diabetes, age or age at diagnosis and diabetes duration are independently associated with macrovascular events and death whereas only diabetes duration is independently associated with microvascular events and this effect is greater in the youngest patients.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B21E01A</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B12B03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Age</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Age</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Edad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Diagnostic</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Diagnosis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Diagnóstico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Durée</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Duration</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Duración</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Microangiopathie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Microangiopathy</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Microangiopatía</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Mortalité</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Mortality</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Mortalidad</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Diabète de type 2</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Type 2 diabetes</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Diabetes de tipo 2</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Artériopathie oblitérante</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Occlusive arterial disease</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Arteriopatía oclusiva</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Endocrinopathie</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Endocrinopathy</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Endocrinopatía</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie métabolique</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Metabolic diseases</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Metabolismo patología</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie des artères</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Arterial disease</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Arteria patología</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie des vaisseaux sanguins</s0>
<s5>24</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Vascular disease</s0>
<s5>24</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Vaso sanguíneo patología</s0>
<s5>24</s5>
</fC07>
<fN21><s1>349</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0277006 INIST</NO>
<ET>Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes</ET>
<AU>ZOUNGAS (Sophia); WOODWARD (Mark); QIANG LI; COOPER (Mark E.); HAMET (Pavel); HARRAP (Stephen); HELLER (Simon); MARRE (Michel); PATEL (Anushka); POULTER (Neil); WILLIAMS (Bryan); CHALMERS (John)</AU>
<AF>The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road/Camperdown, Sydney, NSW 2050/Australie (1 aut., 2 aut., 3 aut., 9 aut., 12 aut.); School of Public Health and Preventive Medicine, Monash University/Melbourne, VIC/Australie (1 aut.); Department of Epidemiology, Johns Hopkins University/Baltimore, MD/Etats-Unis (2 aut.); Baker IDI Heart and Diabetes Institute/Melbourne, VIC/Australie (4 aut.); Research Centre, Centre hospitalier de l'Université de Montréal/Montreal, QC/Canada (5 aut.); The Royal Melbourne Hospital, University of Melbourne/Melbourne, VIC/Australie (6 aut.); University ot Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust/Sheffield/Royaume-Uni (7 aut.); Hôpital Bichat-Claude Bernard and Université Paris 7/Paris/France (8 aut.); International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College/London/Royaume-Uni (10 aut.); Institute of Cardiovascular Science, University College/London/Royaume-Uni (11 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Diabetologia : (Berlin); ISSN 0012-186X; Allemagne; Da. 2014; Vol. 57; No. 12; Pp. 2465-2474; Bibl. 22 ref.</SO>
<LA>Anglais</LA>
<EA>Aims/hypothesis Data are inconsistent regarding the associations between age, age at diagnosis of diabetes, diabetes duration and subsequent vascular complications. Methods The associations between age (or age at diagnosis), diabetes duration and major macrovascular events, all-cause death and major microvascular events were examined in 11,140 patients with type 2 diabetes randomly allocated to intensive or standard glucose control in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Rates were calculated by 5 year baseline age (or age at diagnosis) and diabetes duration strata. Risks were estimated using Cox models adjusted for treatment assignment and HbA<sub>1c</sub>
. Results The mean age (±SD) was 65.8±6.4 years, age at diagnosis was 57.8±8.7 years and diabetes duration was 7.9±6.4 years. Diabetes duration was associated with the risk of macrovascular events (HR 1.13 [95% CI 1.08, 1.17]), microvascular events (1.28 [1.23, 1.33]) and death (1.15 [1.10, 1.20]) whereas age (or age at diagnosis) was only associated with the risk of macrovascular events (1.33 [1.27, 1.39]) and death (1.56 [1.48, 1.64]). No interaction was observed between diabetes duration, age and the risk of macrovascular events or death (both p>0.4). However, an interaction was observed between diabetes duration, age and the risk of microvascular events (p=0.002), such that the effects of increasing diabetes duration were greatest at younger rather than older age. Conclusions/interpretation In patients with type 2 diabetes, age or age at diagnosis and diabetes duration are independently associated with macrovascular events and death whereas only diabetes duration is independently associated with microvascular events and this effect is greater in the youngest patients.</EA>
<CC>002B21E01A; 002B12B03</CC>
<FD>Age; Diagnostic; Durée; Facteur risque; Microangiopathie; Mortalité; Diabète de type 2; Artériopathie oblitérante</FD>
<FG>Endocrinopathie; Maladie métabolique; Pathologie de l'appareil circulatoire; Pathologie des artères; Pathologie des vaisseaux sanguins</FG>
<ED>Age; Diagnosis; Duration; Risk factor; Microangiopathy; Mortality; Type 2 diabetes; Occlusive arterial disease</ED>
<EG>Endocrinopathy; Metabolic diseases; Cardiovascular disease; Arterial disease; Vascular disease</EG>
<SD>Edad; Diagnóstico; Duración; Factor riesgo; Microangiopatía; Mortalidad; Diabetes de tipo 2; Arteriopatía oclusiva</SD>
<LO>INIST-13012.354000504569210060</LO>
<ID>14-0277006</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000179 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000179 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0277006
   |texte=   Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes

Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri